News at CenExel

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

CenExel Psychedelic Facilitators Undergoing Premier Certification Training

CenExel Psychedelic Facilitators Undergoing Premier Certification Training

Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig Goenjian, have developed fit for purpose go-to-clinic strategies encompassing pharmacology, regulatory, and protocol-development consultation services, as well as meticulous clinical trial execution.

Placebo-Control Reminder Script

General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high placebo response has been shown to be increasing as time progresses (Kemp et al., 2010; Loebel et al., 2010; Rief et al., 2009; Tuttle et al., 2015), with such ramifications as several pharma companies reducing or closing their psychiatric as well as general medicine R&D, increased costs for drug development, more inconclusive and failed trials, and delays in the development of new medications (Alphs et al., 2012).